Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.
Shahinfar
Shahnaz
S
Merck Research Laboratories, West Point, Pennsylvania 09486, USA. shahnaz_shahinfar@merck.com
Dickson
Tanya
T
Zhang
Zhongxin
Z
Keane
William F
WF
Brenner
Barry M
BM
D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000150:complications* / Q000453:epidemiology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000453:epidemiology* / Q000209:etiology*; D011507:Proteinuria / Q000150:complications; D012307:Risk Factors
D006454:Hemoglobins; D003404:Creatinine